TY - T1的成立与基线患者的影响ristics on dupilumab efficacy in type 2 asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.04605-2020 VL - 58 IS - 4 SP - 2004605 AU - Busse, William W. AU - Paggiaro, Pierluigi AU - Muñoz, Xavier AU - Casale, Thomas B. AU - Castro, Mario AU - Canonica, G. Walter AU - Douglass, Jo A. AU - Tohda, Yuji AU - Daizadeh, Nadia AU - Ortiz, Benjamin AU - Pandit-Abid, Nami Y1 - 2021/10/01 UR - //www.qdcxjkg.com/content/58/4/2004605.abstract N2 - Severe asthma affects an estimated 5–10% of the total asthma patient population [1]. Various demographic factors, such as sex, age, obesity and age of onset, have been associated with asthma disease severity [2, 3], and the efficacy of asthma treatments has previously been found to vary depending on patient demographics [4, 5].Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlDMedical writing/editorial assistance provided by Grace Manley, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. ER -